Desialylation refers to the process by which the enzyme sialidase shears off the sialic acid at the ends of the glycan chains of glycoproteins. This process exposes glycan ligands on the surface of the cell membrane, which are then recognized and removed by the desialylated glycoprotein receptors of other cells. At CD BioGlyco, we provide our clients with desialylation inhibitor development services and explore the mechanisms by which desialylation occurs.
Fig.1 Development contents of the desialylation inhibitors. (CD BioGlyco)
Technology: Multiple myeloma (MM) cells are treated with salivarylase neuraminidase and tests for changes in cellular toxicity.
Results: MM cells are treated with salivarylase neuraminidase before co-culture with primary natural killer (NK) cells. Siglec-7 is knocked down using the clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 system and pre-designed guide RNAs. MM cells are also treated with daratumumab before co-culture with expanded PNK cells. It is concluded that desialylation with neuraminidase leads to increased degranulation of NK cells compared to sugar buffer control. The high degree of sialylation of MM cells facilitates immune evasion, and targeting the removal of sialic acid strongly enhances the cytotoxicity of NK cells against MM.
At CD BioGlyco, our glycosylation inhibitor development service keeps abreast of technological trends and provides solutions to ensure that every client saves time and effort in developing inhibitors. With our professional research team in the field of glycobiology, we are confident to be your right hand in the field of glycobiology. If you are interested in our services, please feel free to contact us.